Latest on Human Papilloma Virus Vaccine for Cervical Cancer
John Schiller
John Schiller, National Cancer Institute, Bethesda
The human papilloma virus vaccine, which is currently being tested in the prevention of cervical cancer, brings together both infectious disease and cancer. Delegates at the ICAAC conference heard an update on both the anti-cancer and the anti-wart activities of the two vaccines: one from Merck and the other from GlaxoSmithKline.
[audio:https://www.audiomedica.com/podcasting/icaac2005/john_schiller.mp3]
